Glucosyltransferase-1 Deficiency (ALG6-CDG)

Glucosyltransferase-1 deficiency is a rare, inherited metabolic condition. It happens when a gene called ALG6 does not work properly. The ALG6 gene makes an enzyme (a tiny worker protein) in the endoplasmic reticulum of our cells. This enzyme’s job is to add the first glucose sugar onto a growing sugar chain that will be attached to many new proteins. This step is part of N-linked glycosylation — a basic cell process that helps proteins fold, travel, and function.

When ALG6 is weak or missing, many proteins do not get the right sugar chains. As a result, several organs — especially the brain, nerves, eyes, gut, liver, and muscles — may not work as they should. Doctors group this condition under Congenital Disorders of Glycosylation (CDG) and also call it ALG6-CDG or CDG-Ic. It is autosomal recessive (a child gets one faulty copy from each parent). Common signs include feeding problems in babies, weak muscle tone (hypotonia), delayed milestones, seizures, ataxia (poor balance/coordination), eye movement problems (such as strabismus), and sometimes gut protein loss or liver issues. PMC+3Nature+3Orpha.net+3

Glucosyltransferase 1 deficiency is a rare, inherited condition that affects how the body attaches sugar chains to proteins. This “sugar-attachment” process is called N-linked glycosylation. In healthy cells, a small enzyme in the endoplasmic reticulum—named ALG6 (alpha-1,3-glucosyltransferase)—adds the very first glucose sugar to a growing “starter” sugar tree that will later be placed onto many proteins. When ALG6 does not work well because of changes (mutations) in the ALG6 gene, the sugar tree is built incorrectly. As a result, many proteins do not fold properly or cannot do their jobs. This causes a multisystem disorder that most often affects the brain, nerves, eyes, muscles, liver, and sometimes the heart and intestines. The condition is autosomal recessive, which means a child is affected when they receive one non-working ALG6 gene from each parent. MedlinePlus+2PMC+2

Doctors group this disease within the broader family of congenital disorders of glycosylation (CDG). For CDG that impair N-glycosylation, a simple blood “pattern test” of the protein transferrin is often used as a screen, and genetic testing is used to confirm the exact subtype such as ALG6-CDG. PMC+2Mayo Clinic Laboratories+2

---

Other names

People and medical papers may use different names for the same condition:

• ALG6-congenital disorder of glycosylation

• ALG6-CDG

• Congenital disorder of glycosylation type Ic (CDG-Ic)

• Carbohydrate-deficient glycoprotein syndrome type Ic (older term)

• Alpha-1,3-glucosyltransferase I deficiency

• Dolichyl-P-Glc:Man9GlcNAc2-PP-dolichol alpha-1,3-glucosyltransferase deficiency

• Glucosyltransferase 1 deficiency (plain description) MedlinePlus

---

How it works in the body

Inside the endoplasmic reticulum, a “lipid-linked oligosaccharide” (LLO) sugar tree is built step by step. ALG6 adds the first glucose to this tree. Without ALG6’s action, the tree lacks the correct glucose “cap,” protein folding helpers (like calnexin/calreticulin) do not recognize the unfinished glycan, and many proteins are left under-glycosylated, misfolded, or unstable. This broad error explains why symptoms can involve many organs and why neurological problems are common. NCBI+1

---

Types

There is one genetic disease—ALG6-CDG—but doctors often talk about patterns rather than official subtypes. These patterns help set expectations and follow-up:

1. Classic infantile, multisystem pattern. Starts in infancy with low muscle tone (hypotonia), feeding difficulty, poor growth, and developmental delay; seizures and eye movement problems may appear. PMC

2. Neurologic-predominant pattern. Developmental delay, epilepsy, ataxia (balance problems), and proximal muscle weakness are most noticeable; other organs may be mildly involved. Wiley Online Library+1

3. Ophthalmologic/retinal pattern. Strabismus, nystagmus, or progressive retinal problems such as retinitis pigmentosa in some people. NCBI

4. Hepatic/intestinal pattern. Some have liver disease or protein-losing enteropathy, though this is less common than in other CDGs. National Organization for Rare Disorders

5. Cardiac-involved pattern (rare). Dilated cardiomyopathy has been reported in isolated cases. BioMed Central

6. Milder/adolescent-adult pattern. A minority present later with less severe but persistent neurologic or ophthalmic findings; diagnosis often relies on genetics.

These patterns overlap and can change over time for the same person.

---

Causes and risk

There is one root cause: pathogenic variants in both copies of the ALG6 gene. The list below unpacks mechanisms and real-world contexts that explain how and why disease appears or varies among patients:

1. Biallelic ALG6 mutations. The fundamental cause—two harmful changes (from each parent) in ALG6. MedlinePlus

2. Common pathogenic variant p.Ala333Val (c.998C>T). Frequently reported in patients; can be homozygous or compound heterozygous. PMC+1

3. Missense mutations in catalytic regions. Single-letter changes that blunt enzyme activity. BioMed Central

4. Nonsense mutations. Premature “stop” signals that truncate the enzyme. BioMed Central

5. Splice-site mutations. Disrupt message processing, producing faulty enzyme. BioMed Central

6. Frameshift/insertions/deletions. Shift the reading frame and disable ALG6. BioMed Central

7. Large gene deletions. Rare loss of big parts or all of ALG6. BioMed Central

8. Protein misfolding with ER degradation. Some variants make unstable enzyme that is destroyed by quality-control systems. (General CDG mechanism.) NCBI

9. Defective LLO assembly upstream/downstream. When ALG6 is weak, the whole sugar tree assembly stalls, compounding errors. (Pathway context.) NCBI

10. Modifier variants in other glycosylation genes. Mild ALG6 changes can worsen other CDGs, e.g., known interactions with PMM2-CDG. PubMed+1

11. Founder effects. Certain communities have more of a specific ALG6 variant, increasing risk locally. PMC

12. Consanguinity. Parents related by blood increase the chance a child inherits two copies of the same variant. (General genetics principle reflected in CDG case series.) Academia

13. Compound heterozygosity. Two different ALG6 variants—one on each allele—combine to cause disease. BioMed Central

14. Homozygosity by uniparental isodisomy (rare). Both copies from one parent can unmask a recessive variant. (General mechanism in recessive disease; rare in CDG literature.) NCBI

15. ER stress and impaired protein folding cycles. Lack of the glucose “cap” hinders calnexin/calreticulin quality control, amplifying cell stress. (Glycobiology principle.) NCBI

16. Reduced substrate availability (dolichol-P-glucose). If upstream dolichol-linked steps are borderline, an ALG6 defect hits harder. (Pathway logic.) NCBI

17. Temperature/illness stressors. Fevers or infections can temporarily worsen symptoms in many CDGs due to higher metabolic demand. (General CDG clinical observation.) Frontiers

18. Epigenetic or regulatory changes (rare/possible). Non-coding variants may lower ALG6 expression. (General genetics; rare reports.) NCBI

19. Age-related demands. Periods of rapid growth (infancy, childhood) expose the deficit because cells need heavy protein folding. (Clinical patterning.) Frontiers

20. Nutritional fragility. Poor feeding and low weight can further weaken muscle and immunity, magnifying neurologic and systemic features. (CDG care context.) Frontiers in Glycosylation

---

Symptoms and signs

Symptoms vary widely. No single person has all of them, and severity ranges from mild to significant. The items below reflect common patterns reported in case series and clinical summaries:

1. Low muscle tone (hypotonia). Babies feel “floppy,” struggle to hold the head up, and tire easily. PMC

2. Developmental delay. Slower milestones in motor skills and speech; learning difficulties in childhood. PMC

3. Epilepsy or seizures. Many patients develop seizures; types vary. PMC

4. Ataxia (balance problems). Unsteady sitting, standing, or walking; trouble with coordination. Wiley Online Library

5. Proximal muscle weakness. Difficulty rising from the floor or climbing stairs. Wiley Online Library

6. Feeding problems and failure to thrive. Poor suck, reflux, or frequent vomiting in infancy; slow weight gain. PMC

7. Eye movement disorders. Strabismus (crossed eyes) or nystagmus (jerky eye movements) are common. Frontiers in Glycosylation

8. Vision loss from retinal disease. Some develop retinitis pigmentosa causing night blindness and peripheral vision loss. NCBI

9. Stroke-like episodes. Sudden weakness or paralysis that later improves; often triggered by illness. NCBI

10. Behavioral or sleep problems. Autistic features, behavior regulation issues, or poor sleep can occur. PMC

11. Microcephaly (in some). Head size below average due to brain growth differences. Frontiers in Glycosylation

12. Liver involvement. Elevated liver enzymes or liver disease in a subset. National Organization for Rare Disorders

13. Coagulation (clotting) problems. Abnormal lab clotting tests or easy bruising/bleeding in some. NCBI

14. Hearing issues. Some patients report hearing loss. Frontiers in Glycosylation

15. Cardiac involvement (rare). Dilated cardiomyopathy has been described in isolated cases. BioMed Central

---

Diagnostic tests

A) Physical examination (bedside observations)

1. Neurologic exam for tone, strength, and reflexes. Doctors check for hypotonia, weak reflexes, and proximal weakness. This builds the first clinical picture. Frontiers in Glycosylation

2. Developmental assessment. Age-appropriate tools (observation and standardized checklists) gauge motor, speech, and cognitive milestones. Frontiers in Glycosylation

3. Eye exam and ocular alignment check. Detects strabismus, nystagmus, and other eye movement problems. Frontiers in Glycosylation

4. Growth and nutrition review. Weight, length/height, and head size trends help identify failure to thrive or microcephaly. PMC

5. Liver and spleen palpation; skin findings. Looks for organ enlargement or bruising that might signal liver or clotting involvement. National Organization for Rare Disorders

B) Manual/functional bedside tests (simple, hands-on checks)

6. Gowers’ maneuver observation. Watching how a child rises from the floor screens for proximal muscle weakness.

7. Romberg and tandem gait. Standing with feet together, eyes closed; heel-to-toe walking to probe balance (ataxia). Wiley Online Library

8. Finger-to-nose and heel-to-shin. Coordination tests to pick up cerebellar involvement.

9. Ocular pursuit and saccades. Clinician tracks smooth and quick eye movements to characterize ocular motor problems.

10. Feeding/swallowing screen. Simple bedside checks for suck and swallow help flag aspiration risk in infants. PMC

C) Laboratory and pathological tests

11. Transferrin isoelectric focusing (Tf-IEF) or equivalent “CDG transferrin” testing. A frontline blood screen for N-glycosylation defects; shows a type-I pattern in ALG6-CDG. High-performance methods (HPLC/capillary electrophoresis/mass spectrometry) can also be used. PMC+2Mayo Clinic Laboratories+2

12. N-glycan profiling by mass spectrometry. Analyzes the exact sugar structures and helps characterize the glycosylation defect. PubMed

13. Molecular genetic testing. Next-generation sequencing panels or exome/genome sequencing identify pathogenic ALG6 variants; Sanger sequencing confirms. Frontiers

14. Clotting (coagulation) studies. PT/INR, aPTT, and coag factor tests if easy bruising or bleeding occurs. NCBI

15. Liver function tests. ALT, AST, GGT, bilirubin to assess hepatic involvement. National Organization for Rare Disorders

16. Creatine kinase (CK) and basic metabolic panel. Screens for muscle breakdown and general health status; may be normal or mildly altered in some.

D) Electrodiagnostic tests

17. Electroencephalogram (EEG). Records brain wave activity to diagnose and classify seizures and guide anti-seizure therapy. PMC

18. Nerve conduction studies/electromyography (NCS/EMG) when indicated. Helps clarify if weakness relates to nerve or muscle; used case-by-case.

E) Imaging and specialized assessments

19. Brain MRI. May show a thin corpus callosum and cerebral/cerebellar volume loss in some patients—findings that support, but do not by themselves prove, the diagnosis. PMC

20. Ophthalmic testing (fundus exam ± electroretinogram). Looks for retinal degeneration (e.g., retinitis pigmentosa) and guides vision care. Abdominal ultrasound for liver and echocardiogram for rare cardiomyopathy are added when clinically indicated. NCBI+1

Non-pharmacological treatments (therapies and others)

(Each item: description • purpose • mechanism in simple words)

1. Early feeding support — Work with feeding specialists to improve latch, position, and pacing; may use thickened feeds if reflux. Purpose: safer, easier feeding; better growth. Mechanism: reduces choking/reflux and increases calories absorbed.

2. High-calorie nutrition plan — Dietitian builds calorie-dense meals/snacks; frequent small feeds. Purpose: prevent failure to thrive. Mechanism: more energy in, less fatigue at meals.

3. Swallow therapy — Speech-language pathologists train safer swallow. Purpose: cut aspiration risk. Mechanism: strengthen and coordinate muscles.

4. Physical therapy (PT) — Core, balance, and mobility training. Purpose: improve tone, posture, walking. Mechanism: neuro-motor learning and muscle strengthening.

5. Occupational therapy (OT) — Fine-motor and daily skills. Purpose: independence in play, dressing, writing. Mechanism: task-specific practice and adaptive tools.

6. Speech-language therapy — Expressive/receptive language work; AAC if needed. Purpose: better communication. Mechanism: builds language pathways with repetition.

7. Vision management — Patching/strabismus exercises; low-vision aids. Purpose: optimize visual function. Mechanism: supports neural visual development and alignment.

8. Seizure safety education — Family training, rescue plans, water safety, sleep hygiene. Purpose: reduce injury risk. Mechanism: avoids known seizure triggers and prepares for emergencies.

9. Ketogenic diet (select cases, specialist-guided) — High-fat, low-carb medical diet for difficult epilepsy when drugs fail. Purpose: seizure reduction. Mechanism: ketone metabolism can calm brain networks. (Shown helpful in some CDG subtypes; use case-by-case with neurology/dietetics.) PMC

10. Physiatry (rehab medicine) — Bracing, orthoses, spasticity care plans. Purpose: safer gait, fewer contractures. Mechanism: mechanical support and stretching routines.

11. Behavioral therapy — For attention, anxiety, or sleep problems. Purpose: smoother daily routines. Mechanism: structured strategies and positive reinforcement.

12. Educational supports/IEP — School accommodations. Purpose: access to learning. Mechanism: aligns teaching with strengths/needs.

13. Gastroenterology PLE care — Salt/protein optimization; medium-chain fats if helpful; treat edema. Purpose: maintain proteins/fluids. Mechanism: reduces intestinal protein loss impact. NCBI+1

14. Liver-friendly lifestyle — Avoid unnecessary hepatotoxic exposures; routine monitoring. Purpose: protect liver. Mechanism: lowers stress on liver processing.

15. Sleep routine — Regular schedule, dark quiet room. Purpose: fewer seizures/behavior issues. Mechanism: stabilizes brain rhythms.

16. Vaccinations — Stay up to date (no special extra shots typically required). Purpose: prevent infections that worsen nutrition/seizures. Mechanism: primes immune defense.

17. Social work & family support — Benefits navigation, respite care. Purpose: reduce caregiver burnout. Mechanism: practical and emotional support.

18. Genetic counseling — For parents and older patients. Purpose: understand inheritance (25% recurrence risk). Mechanism: informed family planning. Nature

19. Regular multidisciplinary clinics — Neuro, GI, nutrition, PT/OT/SLP, ophthalmology. Purpose: coordinated care. Mechanism: shared plans reduce gaps.

20. Safety adaptations at home — Rails, non-slip mats, helmets for frequent drop attacks if present. Purpose: injury prevention. Mechanism: reduces fall/impact risks.

Most care for CDG conditions is supportive and multidisciplinary. A few CDG types have targeted metabolic therapies; ALG6-CDG currently does not. AAP Publications+1

---

Drug treatments

(Usual choices are individualized. Doses below are typical starting ranges; clinicians adjust by age, weight, liver function, and seizure type.)

Epilepsy (first-line choices vary by patient; mix and match carefully):

1. Levetiracetam (antiseizure). Start pediatrics ~10–20 mg/kg/day in 2 doses; adults ~500 mg twice daily; titrate. Purpose: broad-spectrum seizure control. Mechanism: synaptic vesicle protein 2A modulation. ScienceDirect

2. Lamotrigine. Start low, go slow (risk of rash). Purpose: focal/generalized seizures. Mechanism: stabilizes sodium channels. ScienceDirect

3. Clobazam. Adjunct; weight-based in children. Purpose: drop attacks/tonic-clonic control. Mechanism: GABA-A enhancement. ScienceDirect

4. Topiramate. Start low; titrate. Purpose: generalized/focal seizures, may aid migraines. Mechanism: multiple ion channel and GABA effects. ScienceDirect

5. Valproate (if liver is healthy; use caution with CDG liver involvement). Purpose: broad-spectrum antiseizure. Mechanism: GABAergic; multiple channels. Note: monitor LFTs, platelets. PMC

6. Rescue benzodiazepine (intranasal/buccal midazolam or rectal diazepam). Purpose: stop prolonged seizures at home. Mechanism: fast GABA-A action. ScienceDirect

Tone, movement, comfort:

1. Baclofen (spasticity). Start low; titrate. Purpose: ease stiffness. Mechanism: GABA-B agonist reduces spinal reflexes.
2. Tizanidine (alternative). Purpose: spasticity. Mechanism: α2-adrenergic agonist reduces motor neuron firing.

Sleep/anxiety (when needed):

1. Melatonin (1–5 mg nightly typical start in children). Purpose: sleep onset. Mechanism: circadian signaling.
2. Clonidine at bedtime (specialist-guided). Purpose: sleep, hyperarousal. Mechanism: central α2 action.

Gastrointestinal / nutrition:

1. Proton-pump inhibitor (e.g., omeprazole). Purpose: reflux control to protect airway and feeding. Mechanism: reduces stomach acid.
2. Prokinetic (e.g., erythromycin low dose) if gastroparesis suspected. Purpose: improve gastric emptying. Mechanism: motilin receptor.
3. Loperamide (if diarrhea with PLE; clinician-guided). Purpose: symptom relief. Mechanism: slows gut, improves absorption. PubMed
4. Albumin infusions (if severe hypoalbuminemia from PLE; hospital-guided). Purpose: restore oncotic pressure. Mechanism: replaces lost protein. NCBI
5. Loop diuretic (e.g., furosemide) short-term for edema due to low albumin. Purpose: reduce swelling. Mechanism: diuresis; must pair with protein repletion. NCBI

Coagulation / liver (only if indicated by labs):

1. Vitamin K (if prolonged INR due to deficiency). Purpose: correct coagulopathy. Mechanism: supports clotting factors.
2. Fat-soluble vitamins (A/D/E/K) under dietitian guidance if malabsorption. Purpose: prevent deficiency. Mechanism: repletion.

Pain/headache associated with ataxia or muscle strain:

1. Acetaminophen (paracetamol). Purpose: pain/fever control. Mechanism: central analgesic; liver-dose limits apply.
   19) Ibuprofen (if kidneys and stomach are healthy). Purpose: pain/inflammation. Mechanism: COX inhibition.

Refractory epilepsy (specialist use):

1. Ketogenic diet–adjunct prescriptions (vitamin/mineral packets, citrate to prevent stones) or other add-on anti-seizure meds as the team chooses. Purpose: enable a supervised ketogenic program or advanced regimens. Mechanism: nutritional ketosis plus targeted pharmacology. PMC

Because ALG6-CDG can include liver or nutrition issues, medication choices and doses must be individualized and monitored by clinicians experienced in epilepsy, gastroenterology, and metabolic genetics.

---

Dietary / molecular supplements

(Use only with your clinician/dietitian; evidence ranges from limited to moderate across CDG types.)

1. Coenzyme Q10 — cell energy support; sometimes tried for fatigue/mitochondrial stress.

2. L-carnitine — may help fatty-acid transport; consider if low levels from malnutrition or PLE.

3. Riboflavin (B2) — cofactor in energy pathways; sometimes used in neurometabolic disorders.

4. Thiamine (B1) — supports carbohydrate metabolism; consider in poor intake.

5. Pyridoxine (B6) — cofactor in neurotransmitter synthesis; occasionally supports seizure control.

6. Vitamin D — bone and immune health, often low in children with limited mobility.

7. Zinc — supports growth/immune function if deficient.

8. Magnesium — may aid sleep/muscle relaxation if low.

9. Omega-3 fatty acids — general neurodevelopmental and anti-inflammatory support.

10. Multivitamin with fat-soluble vitamins — especially if malabsorption is present.

Nutrition reviews in CDG emphasize targeted supplementation and, for specific subtypes (not ALG6), monosaccharide therapy; overall, diet remains supportive and individualized. PMC+1

---

Drugs in the “immunity-booster / regenerative / stem-cell

There are no approved immune-booster, regenerative, gene, or stem-cell drugs for ALG6-CDG today. Research across the CDG field explores:

1. Gene therapy (AAV or mRNA delivery) — conceptually replaces the enzyme; still preclinical/early translational in many CDGs.

2. Pharmacologic chaperones — small molecules that help misfolded enzymes work better; investigational.

3. Substrate supplementation / bypass strategies — work in a few CDGs (e.g., mannose for MPI/CDG-Ib), but not proven for ALG6.

4. mRNA therapy / genome editing — experimental platforms.

5. Drug repurposing — systematic searches for existing meds that improve glycosylation; early signals only.

6. Cell/organ-targeted delivery technologies — being studied to reach liver/brain.

If you are interested in trials, discuss clinical-trial options with a metabolic center; eligibility is narrow and safety monitoring is strict. MDPI+3PMC+3GIM Journal+3

---

Surgeries

1. Gastrostomy tube (G-tube) — for severe feeding difficulty or aspiration. Why: ensure safe calories and meds; cut hospitalizations.

2. Fundoplication (anti-reflux surgery) — for life-limiting reflux not controlled by meds. Why: protect lungs and feeding comfort.

3. Strabismus surgery — for significant eye misalignment. Why: improve alignment, depth perception, and cosmesis.

4. Orthopedic procedures — tendon releases or scoliosis surgery if contractures or spinal curves cause pain or function loss. Why: improve comfort, seating, or mobility.

5. Central line or port placement (select cases) — if long-term infusions are required (e.g., nutrition or albumin). Why: safer vascular access.

---

Prevention tips (practical)

1. Keep vaccinations current (including flu).

2. Build a written seizure plan and teach caregivers.

3. Protect sleep — regular schedule and screen-free wind-down.

4. Avoid prolonged fasting — small, regular meals/snacks.

5. Prevent falls — safe shoes, grab bars, tidy floors.

6. Oral health — reduce aspiration risk from dental issues.

7. Hand hygiene — infections worsen nutrition and seizures.

8. Medication reconciliation — always check for liver-toxic or sedating drug combinations.

9. Sun and hydration safety — heat and dehydration can trigger seizures.

10. Regular specialty checkups — neuro, GI, nutrition, ophthalmology.

---

When to see a doctor (red flags)

• New or worsening seizures, long seizures, or repeated clusters.

• Feeding refusal, choking, vomiting blood, or dehydration.

• Puffy swelling (face/legs), big belly, or shortness of breath (possible low protein/PLE).

• Yellow eyes/skin, easy bruising/bleeding, or very dark urine (possible liver issue).

• Sudden loss of skills, severe headache, or behavior changes.

• Any concern that worries you — earlier is better.

---

What to eat and what to avoid

• Eat: frequent, energy-rich meals; added healthy fats (as advised); balanced protein; fruits/vegetables for fiber and micronutrients; adequate fluids; if on ketogenic diet for seizures, follow medical recipes exactly.

• Avoid: long gaps between meals; choking-risk textures if swallow is unsafe; unnecessary herbal “cures”; excess acetaminophen or alcohol (for adolescents/adults) that strain the liver; unsupervised restrictive diets.

Diet plans in CDG are individualized; some subtypes have special sugar therapies, but ALG6-CDG does not. Work with a dietitian. PMC

---

FAQs

1. Is ALG6-CDG the same as GLUT1 deficiency? No. GLUT1 deficiency is a glucose transporter problem at the blood-brain barrier; ALG6-CDG is a protein sugar-attachment problem inside cells. NCBI+1

2. How common is ALG6-CDG? Very rare; far below 1 in a million. orphanet-preprod.atolcd.com

3. How is it inherited? Autosomal recessive (25% chance each pregnancy if both parents are carriers). Nature

4. What are the most common signs? Feeding difficulty, low muscle tone, developmental delay, ataxia, seizures, strabismus. PMC

5. How do doctors screen for CDG? Transferrin isoelectric focusing (TIEF/IEF) or mass-spec isoforms. Frontiers+1

6. How is ALG6-CDG confirmed? Genetic testing of ALG6. Mayo Clinic Laboratories

7. Is there a cure? Not yet; treatment is supportive and symptom-based. AAP Publications

8. Are there diet cures? No cure; standard nutrition is supportive. Ketogenic diet may help refractory seizures in select CDG cases under expert care. PMC

9. Can PLE occur? Yes, in a minority; it causes low blood protein and swelling and needs GI care. Genetic Diseases Info Center

10. Which anti-seizure drug is best? It depends on seizure type, age, and liver status. Teams often start with levetiracetam or lamotrigine; others are added as needed. ScienceDirect

11. Will my child walk/talk? Many children make progress with therapy; outcomes vary widely. Early supports help. Orpha.net

12. Is liver disease common? Some patients show liver involvement; regular monitoring guides care. Genetic Diseases Info Center

13. What specialists should we see? Metabolic genetics, neurology, GI/nutrition, PT/OT/SLP, ophthalmology. AAP Publications

14. Are clinical trials available? Trials across CDG exist but are limited; ask your metabolic center about eligibility. ScienceDirect

15. Where can we learn more? Orphanet and patient-friendly CDG resources summarize ALG6-CDG and supports. Orpha.net+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 12, 2025.